Leukemia Clinical Trial
Official title:
Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to kill cancer cells or stop them from growing. Monoclonal antibodies, such
as rituximab and alemtuzumab, can block cancer growth in different ways. Some find cancer
cells and help kill them or carry cancer-killing substances to them. Others interfere with
the ability of cancer cells to grow and spread. It is not yet known whether giving
fludarabine and cyclophosphamide together with rituximab is more effective than giving
fludarabine and cyclophosphamide together with alemtuzumab in treating B-cell chronic
lymphocytic leukemia.
PURPOSE: This randomized phase III trial is studying giving fludarabine together with
cyclophosphamide and rituximab to see how well it works as first-line therapy compared with
giving fludarabine together with cyclophosphamide and alemtuzumab in treating patients with
B-cell chronic lymphocytic leukemia.
Status | Completed |
Enrollment | 178 |
Est. completion date | July 2013 |
Est. primary completion date | January 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
DISEASE CHARACTERISTICS: Inclusion Diagnosis of B-cell chronic lymphocytic leukemia (CLL), meeting the following criteria: - Binet classification stages B or C - Del 17 p (FISH) negative (< 10 % positives cores) - Matutes score 4 or 5 Exclusion Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma, or prolymphocytic leukemia) PATIENT CHARACTERISTICS: Exclusion ECOG performance status = 2 - Life expectancy < 6 months - Creatinine clearance < 60 mL/min - Total bilirubin > 2 x upper limit of normal (ULN) - Gamma glutamyltransferase or transaminase levels > 2 x ULN - Cumulative illness rating scale > 6 - HIV seropositivity - Hepatitis B or C seropositivity (unless clearly due to vaccination) - Clinically significant autoimmune anemia - Active bacterial, viral, or fungal infection - Active second malignancy currently requiring treatment (except basal cell carcinoma or in situ endometrial carcinoma) and/or less than 5 years complete remission after breast cancer - Any severe comorbid conditions including, but not limited to, any of the following: - Class III or IV heart failure - Recent myocardial infarction - Unstable angina - Ventricular tachyarrhythmias requiring ongoing treatment - Severe chronic obstructive pulmonary disease with hypoxemia - Uncontrolled diabetes mellitus - Uncontrolled hypertension - Concomitant disease requiring prolonged use of corticosteroids (> 1 month) - Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs - Contraindication to the use of rituximab or alemtuzumab according to Summary of Product Characteristics - Any coexisting medical or psychological condition that would preclude participation in the required study procedures - Any mental deficiency preventing proper understanding of the requirements of treatment - Person under law control - Pregnant or breastfeeding women - Fertile patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study PRIOR CONCURRENT THERAPY: Inclusion - No prior chemotherapy, radiotherapy, or immunotherapy for CLL - Corticosteroids within the past month allowed |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Centre Henri Becquerel | Rouen |
Lead Sponsor | Collaborator |
---|---|
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival at 36 months | 36 months follow up | No | |
Secondary | Disease-free survival | 36 months follow up | No | |
Secondary | Event-free survival | 36 months follow up | No | |
Secondary | Overall survival | 36 months follow up | No | |
Secondary | Time to next treatment | 36 months follow up | No | |
Secondary | Overall response rate (complete response [CR] and partial response [PR]) | 36 months follow up | No | |
Secondary | Duration of phenotypic, molecular, NCI complete and partial responses | 36 months follow up | No | |
Secondary | Response rates and survival times in biological subgroups | 36 months follow up | No | |
Secondary | Treatment-related adverse effects | 36 months follow up | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |